tradingkey.logo

Amicus rises after BioMarin's $4.8 billion buyout deal

ReutersDec 19, 2025 1:15 PM

Shares of Amicus Therapeutics FOLD.O rise 30% to $14.16 premarket

BioMarin Pharmaceutical BMRN.O to buy FOLD in an all-cash deal worth about $4.8 billion

BMRN will pay $14.50 per share for FOLD, a premium of 33.1% to the stock's last close

BMRN gains access to FOLD's treatments for genetic disorders Fabry disease and Pompe disease

Up to last close, FOLD shares up 15.6% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI